Detecting Anti-Infliximab Antibodies in Rheumatoid Arthritis Patients
Author Information
Author(s): van den Bemt Bart JF, den Broeder Alfons A, Wolbink GJ, Hekster Yechiel A, van Riel Piet LCM, Benraad Bart, van den Hoogen Frank HJ
Primary Institution: Sint Maartenskliniek, Nijmegen, The Netherlands
Hypothesis
At what moment do patients develop low/no infliximab trough levels and/or detectable anti-infliximab levels during an infusion cycle?
Conclusion
Most patients with anti-infliximab antibodies have detectable levels halfway through an infusion cycle, indicating they may be exposed to ineffective infliximab levels.
Supporting Evidence
- 27 patients were included in the study.
- Infliximab levels decreased from 77.0 mg/l to 0.0 mg/l during the infusion cycle.
- 26% of patients had detectable anti-infliximab antibodies halfway through the infusion cycle.
- Patients with detectable antibodies had significantly lower infliximab levels compared to those without.
Takeaway
Many patients with rheumatoid arthritis on infliximab have low levels of the drug halfway through their treatment, which means it might not be helping them.
Methodology
This was a descriptive open-label cohort study assessing (anti-)infliximab levels at multiple time points during one infusion cycle.
Potential Biases
The study population may not represent all rheumatoid arthritis patients due to the exclusion of non-responders.
Limitations
The study had a limited number of patients and could not assess risk factors for anti-infliximab antibody formation due to selection bias.
Participant Demographics
{"age":"61.6 ± 10.0 years","gender":"56% women","median_disease_duration":"11.2 years","previous_DMARDs":"2.5","rheumatoid_factor_positive":"78%"}
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website